{"id":"W4322771875","doi":"10.1158/1538-7445.sabcs22-ot2-16-05","title":"Abstract OT2-16-05: Safety Analyses of NRG BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-Positive Metastatic Breast Cancer (MBC)","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pertuzumab; Taxane; Metastatic breast cancer; Atezolizumab; Internal medicine; Oncology; Clinical endpoint; Placebo; Trastuzumab; Randomized controlled trial; Breast cancer; Ixabepilone; Interim analysis; Surgery; Cancer; Nivolumab; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00276588,0.0006267137,0.002953283,0.001570211,0.0002149683,0.00003963075,0.0005210667,0.0001980166,0.002335389],"category_scores_gemma":[0.0003460466,0.000428044,0.0004217683,0.004300707,0.00167154,0.0003122249,0.0001767066,0.001115674,0.00001838997],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002469614,"about_ca_system_score_gemma":0.003822819,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03362893,"about_ca_topic_score_gemma":0.01023957,"domain_scores_codex":[0.9930571,0.0005580283,0.001759105,0.001020085,0.002283108,0.001322552],"domain_scores_gemma":[0.9940903,0.002336337,0.0007221194,0.0008811377,0.001549905,0.0004202336],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9447882,0.001400682,0.00006106189,0.001100975,0.002465935,0.0005367522,0.001642362,0.006517139,0.006360568,0.00005099391,0.0001864148,0.03488893],"study_design_scores_gemma":[0.9570276,0.00245649,0.0004158338,0.003418825,0.0006229374,0.0001421237,0.00167123,0.0004696246,0.03287163,0.0001141428,0.0003469142,0.0004426608],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816657,0.003095926,0.0005042733,0.003232642,0.000243857,0.008961517,0.001598845,0.0001073831,0.0005898521],"genre_scores_gemma":[0.9889462,0.005194923,0.0001736752,0.00006168582,0.0003988351,0.003498882,0.0002055312,0.0001380687,0.00138219],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03444627,"threshold_uncertainty_score":0.9998171,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1641459642196728,"score_gpt":0.485260842463795,"score_spread":0.3211148782441222,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}